Last reviewed · How we verify
CART20
At a glance
| Generic name | CART20 |
|---|---|
| Sponsor | Beijing Biohealthcare Biotechnology Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CART20 CI brief — competitive landscape report
- CART20 updates RSS · CI watch RSS
- Beijing Biohealthcare Biotechnology Co.,Ltd portfolio CI